Results 371 to 380 of about 1,198,663 (392)
Some of the next articles are maybe not open access.

Adjuvant Chemotherapy

Thoracic Surgery Clinics, 2020
Five-year survival rates for patients with early-stage non-small cell lung cancer have room for improvement. Adjuvant chemotherapy results in a small but significant increase in overall survival at 5 years. Efforts to improve outcomes by intensifying adjuvant treatment, utilizing cancer-specific vaccines or tyrosine kinase inhibitors in unselected ...
Jessica A, Hellyer, Heather A, Wakelee
openaire   +2 more sources

Mechanisms of adjuvancy: I?metal oxides as adjuvants

Vaccine, 1997
The exact mechanism of how immune adjuvants function still remains largely unknown, despite their long history of use. This work reports the properties of alum and the related compounds Al(OH)3 or Al2O3. Experiments were performed in rats to determine the relative adjuvancy of silica, talc, ground glass, Al2O3, SnO2, ZrO2, hematite and magnetite ...
C. J. van Oss   +4 more
openaire   +3 more sources

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

Vaccine, 2001
Elderly people and subjects with underlying chronic diseases are at increased risk for influenza and related complications. Conventional influenza vaccines provide only limited protection in the elderly population. In order to enhance the immune response to influenza vaccines, several adjuvants have been evaluated. Among these, an oil in water adjuvant
openaire   +3 more sources

T-cell adjuvants

International Journal of Immunopharmacology, 1994
T-cell adjuvancy involves the use of agents to stimulate preferentially delayed type hypersensitivity (DTH). Traditional adjuvants like Alum, Freunds, muramyl peptides, and endotoxins are not selective. Natural infection (e.g. vaccinia) may yield selective DTH. Low dose cyclophosphamide (CY) with mycobacteria was the first experimental T-cell adjuvant.
openaire   +3 more sources

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Journal of the American Medical Association (JAMA), 2013
IMPORTANCE The prognosis for patients with pancreatic cancer is poor, even after resection with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced pancreatic cancer, but its effect on survival in the adjuvant setting has ...
H. Oettle   +12 more
semanticscholar   +1 more source

Adjuvant synergy: The effects of nasal coadministration of adjuvants

Immunology & Cell Biology, 2004
Modern peptide and protein subunit vaccines suffer from poor immunogenicity and require the use of adjuvants. However, none of the currently licensed adjuvants can elicit cell‐mediated immunity or are suitable for mucosal immunization. In this study we explored the immunological effect of nasal co‐administration of adjuvants with distinct functions ...
Sterghios Moschos   +3 more
openaire   +3 more sources

Immunological adjuvants IV. Relationship between adjuvant activity and antigenicity in mycobacterial adjuvant

Experientia, 1971
Wahrend sich bei Endotoxinen der Adjuvanseffekt proportional zur Antigenitat verhalt, ist diese Beziehung bei dem aus Tuberkelbazillen isolierten Wachs D nicht der Fall.
Tatsuro Ishibashi   +3 more
openaire   +3 more sources

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Journal of Clinical Oncology, 2009
PURPOSE Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative intent for stage II or III colon cancer who received bolus plus continuous-infusion fluorouracil plus leucovorin (LV5FU2) with
T. André   +10 more
semanticscholar   +1 more source

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Nature, 2021
T. Powles   +26 more
semanticscholar   +1 more source

Vaccine Adjuvants

Clinical Infectious Diseases, 1980
Nonreplicating, purified subunit or synthetic viral vaccines of the future are likely to be weak immunogens that will require immunopotentiation if they are to be effective. These marginal vaccines could be improved by combination with potent and safe immunologic adjuvants. The use of adjuvants should also reduce the amount of purified antigen required
openaire   +2 more sources

Home - About - Disclaimer - Privacy